WorkCompWire: Shore Up the Home Health Staffing Shortage with a Deep Bench of Expertise
Explore how Bob Smith addresses the growing home health staffing shortage in workers' compensation by leveraging a nationwide network of skilled caregivers to ensure consistent, high-quality care for injured employees.
WorkCompWire: How Outdated Imaging Equipment is Impacting Quality of Care and Claim Costs
Ted Smith discusses how outdated diagnostic imaging equipment affects care quality and drives up workers’ compensation claim costs—highlighting the importance of modern technology in improving outcomes and reducing inefficiencies
Guidewire Connections 2019
Guidewire Connections is the conference for people who u
The Difference Between Specialty Drugs, Biologics, and Biosimilars
3 MIN READ
In the world of workers’ comp pharmacy benefit management, understanding generics vs. brand name drugs, narcotics, muscle relaxants, and compounds now seems relatively simple as compared with the latest pharmacy terminology: specialty drugs, biologics, and biosimilars. These terms are making the headlines with increased frequency, and while some think they are interchangeable, there truly are distinctions between them.
Topical Trend Differences: Understanding Drug Mix
1 MIN READ
Topical medication cost and utilization continue to decrease in the managed population. However, in the unmanaged space we continue to see year-over-year increases in both cost and utilization. Understanding the differences in the types of topical medications dominating each space can help us to target pharmaceutical management strategies that weed out price opportunists and ensure the most appropriate care.
Mitchell 2019 mPower Conference
Join us for Mitchell’s annual customer gathering, the Mi
Top Therapeutic Classes by Cost and Utilization
1 MIN READ
Therapeutic classes falling within the top 10 most utilized and costly categories had some interesting, although not altogether unsurprising, movement. View out our latest video blog which addresses some of the changes and trends seen for the top ten drug classes both in- and out-of-network.